tryptanthrine has been researched along with Psoriasis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H; Wang, J; Wang, S; Xiong, Y; Zhou, X | 1 |
| Chang, CH; Chang, CN; Chang, CY; Cheng, HM; Fang, WY; Kuo, YZ; Lin, JY; Pan, SC; Wu, LW | 1 |
2 other study(ies) available for tryptanthrine and Psoriasis
| Article | Year |
|---|---|
Tryptanthrin ameliorates imiquimod-induced psoriasis in mice by suppressing inflammation and oxidative stress via NF-κB/MAPK/Nrf2 pathways.
Topics: Animals; Cytokines; Disease Models, Animal; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Psoriasis; Signal Transduction; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2023 |
The anti-TH17 polarization effect of Indigo naturalis and tryptanthrin by differentially inhibiting cytokine expression.
Topics: Animals; Cell Proliferation; Cytokines; Disease Models, Animal; Drugs, Chinese Herbal; Endothelial Cells; Humans; I-kappa B Kinase; Immunosuppressive Agents; Inflammation Mediators; Jurkat Cells; Keratinocytes; Mice, Knockout; Nuclear Receptor Subfamily 1, Group F, Member 3; Phenotype; Psoriasis; Quinazolines; Skin; Th17 Cells; U937 Cells | 2020 |